We’re here to help bridge the gap between the research bench and patient treatments. By working with you in the assay design & development process and its clinical validation, we can help cut down the time to bring these assays to the clinic.
Through our open Call for Diagnostics campaign we are always looking for potential collaborative projects with academic scientists or diagnostics companies on molecular diagnostic assay development and validation.
You’ll benefit from our resources and expertise
By collaborating with us you have access to all the resources you’ll need to help you progress your research-developed assays towards clinical use:
- Molecular diagnostics expertise and industry experience
- Properly controlled development environment certified to ISO13485
- Connections to potential industry partners and diagnostic platforms
By taking your opportunity through pre-clinical proof of concept, we will add industry recognised credibility to exciting cutting edge research. We do this through quality managed assay development and rigorous validation testing in an appropriate sample population. We can also help you pinpoint the best stage at which to approach commercial partners.
Academic and charity funded research
We recognise that funding can be difficult to access for diagnostics development and so we invest our time and resources at no cost to you. We can also look at investing in the development of your research and at supporting funding applications.
We also recognise that industry will often have access to promising science that needs further development work and resources. We will always be keen to discuss partnering options to stimulate the development of research.
Types of early stage projects we are looking to co-develop
We’re interested in molecular diagnostics (RNA/DNA based tests) focusing on:
- Infectious diseases
- Precision medicine
We’re also interested in helping develop enabling tools including extraction methodologies and novel, point of care, assay platforms.
Our work in action – tackling antibiotic resistance
We worked with Renishaw Diagnostics to develop a novel test for the detection of carbapenemase genes, which are associated with antibiotic resistance. This diagnostic test is now available as an RUO kit, marketed by Bruker.